Effective June 17, 2019, Procollagen 1 intact N-terminal (P1NP) testing will change from a sendout reference radioimmunoassay test to Mayo Medical Laboratories to an in-house chemiluminescence assay performed by Spectrum Health Regional Laboratory.
Effective immediately, QuantiFERON®-TB Gold test (QFT), the industry-leading Interferon-gamma Release Assay (IGRA) for TB detection used at Spectrum Health Regional Laboratory is being replaced by the QuantiFERON-TB Gold Plus (QFT-Plus).
The QFT-Plus is now optimized with innovative tuberculosis-specific antigens that elicit both CD8 and CD4 T cell responses, enabling a more comprehensive assessment of cell-mediated immune response to TB infection. The test principle, procedures, and specimen handling will remain the same with the one exception being that the collection kit will now consist of four tubes instead of three. Three-tube collections can no longer be accepted and will thus be canceled.
If you have three-tube collection kits, please order new four-tube collection kits in Lawson (#54909) or via the Lab Supply Order Form.
Please direct urgent questions to the Laboratory Call Center at 616-774-7721 or for non-urgent inquiries use the “contact us” link above.
The diagnostic evaluation of allergic disease occurs in the context of a patient’s complete clinical presentation. Important factors include, age, clinical signs and symptoms, relevant allergen exposures, and the performance characteristics (sensitivity, specificity, and predictive values) of the allergy tests themselves. Allergy tests yield information about sensitization to allergens, which is not always equivalent to allergic hypersensitivity (i.e., sensitivity); thus, interpretation in the context of clinical history is essential for accurate diagnosis.